Tagrisso (osimertinib) / AstraZeneca - LARVOL DELTA

Endocrine manifestations of lung adenocarcinoma with epidermal growth factor receptor mutation mimicking tuberculosis: A case report and literature review. (PubMed, Qatar Med J) - "Treatment with targeted therapy involving osimertinib resulted in clinical improvement...The presence of pituitary metastasis further complicates the clinical picture, emphasizing the importance of considering rare metastatic sites in the differential diagnosis of lung adenocarcinoma. Timely recognition and appropriate management are crucial for optimizing outcomes in such complex cases, highlighting the need for a multidisciplinary approach in oncological and endocrine care."

Journal • Endocrine Disorders • Infectious Disease • Lung Adenocarcinoma • Lung Cancer • Metabolic Disorders • Nephrology • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Solid Tumor • Tuberculosis • EGFR

Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis. (PubMed, Lung Cancer) - "Osimertinib is associated with a modest but clinically significant risk of cardiotoxicity, particularly QT prolongation. These findings support the need for routine cardiac monitoring in high-risk patients and emphasize the importance of standardized cardiotoxicity reporting in future trials to enhance the safety profile of Osimertinib in NSCLC treatment."

Journal • Retrospective data • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study. (PubMed, Lung Cancer) - "Osimertinib combined with full dose anlotinib showed manageable safety profile and encouraging efficacy, deserving further investigation."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Targeting both wild-type EGFR and its drug-resistant mutants with erlotinib-aptamer conjugates. (PubMed, Eur J Med Chem) - "Importantly, LY-dE#5 drives not only the downregulation of the wild-type but also the mutants which include 19del, L858R/T790M, 19del/T790M/C797S, and L858R/T790M/C797S, exhibiting superior antitumor activity over Osimertinib. Further in vitro and in vivo studies demonstrate that LY-dE#5 effectively suppresses the growth of EGFR-driven cancer cells. These data indicate that the erlotinib-aptamer conjugate is an efficient pan-EGFR degrader that holds the translational potential for cancer treatment to overcome the common drug-resistance issues of EGFR-TKIs."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • EGFR • IGF2

An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib. (PubMed, Front Pharmacol) - "Molecular dynamics simulations (100 ns) demonstrated stable binding of osimertinib-AKT1/ALB complexes, with average RMSD values of 0.52 nm and 0.50 nm, respectively, and binding free energies of -44.63 kJ/mol (AKT1) and -42.92 kJ/mol (ALB). This study clarifies osimertinib-induced CAR mechanisms involving multi-target interactions and pathway dysregulation, aiding clinical safety and future research."

Adverse events • Journal • Cardiomyopathy • Cardiovascular • CASP3 • EGFR • ER

FL30: an epidermal growth factor kinase inhibitor overcoming T790M and C797S mutations through unique conformational modulation mechanism. (PubMed, Int J Biol Macromol) - "The IC50 comparable to the Osimertinib - one of the most renowned EGFR-TKIs - emphasizes the remarkable success of the design approach...Kinetic studies, molecular modeling, and Plasmon Internal Reflection Surface-Enhanced Infrared Absorption (PIR-SEIRA) microscopy suggests that FL30 binds to the orthosteric site while inducing the transition of the mutant EGFR toward an inactive-like state. These findings highlight FL30's potential for further optimization and propose a novel approach for developing targeted therapies that combine orthosteric binding with allosteric modulation."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGF

Remarkable improvement of metastatic occipital condyle syndrome in a patient with lung adenocaricinoma treated with osimertinib (PubMed, Rinsho Shinkeigaku) - "The subsequent administration of osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, led to a reduction in the size of the tumor, as well as improvements in the hypoglossal nerve palsy and occipital pain. It is imperative to note that occipital condyle syndrome signifies the metastasis of a malignancy to the base of the skull, necessitating meticulous observation and management."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • EGFR

Traditional Chinese Medicines as Anticancer Agents for Non-Small Cell Lung Cancer with EGFR Mutations: A Review. (PubMed, Drug Des Devel Ther) - "Osimertinib is currently the first-line treatment choice for patients with EGFR L858R/T790M mutations, however, as to other EGFR-TKIs, resistance inevitably occurs...TCM achieves these effects by regulating multiple signaling pathways and mechanisms, while also exhibiting synergistic interactions with EGFR tyrosine kinase inhibitors (TKIs). This review highlights the mechanisms through which TCM influences NSCLC patients harboring EGFR mutations, offering a promising therapeutic strategy for those with EGFR-TKI resistance."

Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR

PROGNOSTIC AND FUNCTIONAL IMPACT OF EGF-JAK/STAT PATHWAY MUTATIONS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (ICML 2025) - "Western blot analysis was used to examine activation of downstream signaling pathways and response to EGFR inhibitors gefitinib and osimertinib. EGFR mutations define a distinct subset of AITL with poor prognosis and aberrant activation of JAK/STAT signaling. Their presence in dominant tumor clones and their ability to activate oncogenic signaling suggest a driver role in AITL. The suppression of signaling by EGFR inhibitors supports the potential for targeted therapies in EGFR-mutant AITL."

IO biomarker • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • EGF • STAT5

Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study (Lung Cancer) - P1/2 | N=25 | AUTOMAN (NCT04770688) | "25 eligible patients were enrolled. The RP2D is osimertinib 80mg, once daily and anlotinib (12 mg/day orally, 14 days on and 7 days off). Adverse events of any cause (TEAE) and any grade was observed in 24 (96.0%) patients. 8 (32.0%) patients experienced grade 3 TEAE. Serious adverse events were reported in 4 (16.0%) patients. In FAS population (defined as patients who received at least one dose of study drugs), ORR and DCR was 60.0% (15/25 patients, 95% CI, 38.7%-78.9%) and 88.0% (22/25 patients, 95% CI, 68.8%-97.5%), respectively. Median PFS and OS were 31.5 months (95%CI, 17.9 months-NE) and not reached, respectively, with 36 months PFS and OS rate were 31.9% (95%CI, 17.3%-58.8%) and 74.3% (95% CI, 58.5%-94.4%), respectively."

P1/2 data • Non Small Cell Lung Cancer

Second-line treatments in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) beyond osimertinib (ERS 2025) - No abstract available

Clinical • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Real-World Cardiovascular Risk Comparison of First-Line Osimertinib and Earlier Generation EGFR-TKIs in EGFR-Mutated NSCLC: A TriNetX USA Network Analysis (ERS 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiovascular • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

Interim Analysis of pulmonary tolerability from the multicenter ROSE Study: Radiation during Osimertinib Treatment Safety and Efficacy Cohort (ERS 2025) - No abstract available

Clinical • Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

Dermatologic Adverse Event Mitigation and Management Strategies with Amivantamab + Lazertinib Therapy for Advanced Non-Small Cell Lung Cancer: A Vodcast. (PubMed, Target Oncol) - "The MARIPOSA study assessed amivantamab + lazertinib versus osimertinib in previously untreated patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer. While dermatologic AEs are common, effective proactive management strategies, as demonstrated in the COCOON study, can help reduce the incidence and severity of dermatologic AEs. Prioritizing education for healthcare providers and patients will facilitate timely identification and proactive and reactive management of these events, ultimately improving the treatment experience for patients undergoing therapy with amivantamab and lazertinib."

Adverse events • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Case Report: Osimertinib-induced acute interstitial lung disease. (PubMed, Front Pharmacol) - "Despite discontinuation of osimertinib and administration of aggressive supportive care, her clinical condition continued to deteriorate, ultimately resulting in a fatal outcome. This case underscores the importance of monitoring respiratory symptoms in patients receiving EGFR-TKIs, promptly diagnosing ILD, and implementing early intervention to mitigate adverse outcomes."

Journal • Interstitial Lung Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov) - P=N/A | N=130 | Recruiting | Sponsor: N-Power Medicine

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Osimertinib Dose Optimization Guided by Therapeutic Drug Monitoring in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Case series. (PubMed, Clin Lung Cancer) - No abstract available

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Epidermal Growth Factor Receptor Kinase Domain Duplication in Lung Adenocarcinoma with Response to Osimertinib: A Case Report and Literature Review. (PubMed, Case Rep Oncol) - "A 54-year-old male was diagnosed with metastatic NSCLC and progressed on multiple lines of therapies: carboplatin-pemetrexed-pembrolizumab, cisplatin-docetaxel, and durvalumab-tremelimumab over a 6-month period. Liquid and tissue NGS should be used in combination to guide treatment and monitor treatment response. Osimertinib may be particularly effective in metastatic NSCLC with EGFR-KDD mutations."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED). (PubMed, Ther Adv Med Oncol) - "Meanwhile, the FLAURA study revealed shorter PFS with osimertinib (OSI) for L858R mutation than Ex19del mutation, with poorer PFS in the Japanese subset than in the overall population. To the best of our knowledge, this is the first retrospective study focusing on L858R mutations associated with the RELAY regimen, providing the corresponding real-world data. UMIN Clinical Trials Registry identifier: UMIN000052047."

IO biomarker • Journal • Observational data • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • PD-L1

Identifying the genomic landscape of EGFR-mutant lung cancers with CNS metastases. (PubMed, Ann Oncol) - "Patients with atypical EGFR mutations or acquired CNS metastases on osimertinib have worse outcomes. Comparative NGS profiling of intra- and extracranial tumors suggest that CNS dissemination is driven by mechanisms beyond single-gene alterations."

Journal • Brain Cancer • CNS Tumor • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CARD11 • EGFR • MDM2

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of belantamab mafodotin for multiple myeloma, asciminib for leukemia, osimertinib for lung cancer, amivantamab for lung cancer, and pembrolizumab for pleural mesothelioma in Japan. (PubMed, Int J Clin Oncol) - No abstract available

Japanese regulatory • Journal • Hematological Malignancies • Leukemia • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Multiple Myeloma • Oncology • Pleural Mesothelioma • Solid Tumor

Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinion. (PubMed, Int J Cancer) - "The panel recommended careful selection of patients for osimertinib+chemotherapy or lazertinib+amivantamab based on safety and efficacy profile, patient age, and disease status. For lazertinib+amivantamab, measures to mitigate adverse events such as the use of pre-medication with steroids, prophylactic anticoagulants, and dose modification are recommended. For patients progressing on one of the combination regimens, experts recommended repeat NGS testing and continued treatment with chemotherapy."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Peking University Shenzhen Hospital

Biomarker • New P2 trial • Oncology

PET/Fluorescence Dual-Modal Tracing Drug Delivery Probe for Targeting and Overcoming Molecular Targeted Therapy Resistance in Lung Cancer (SNMMI 2025) - "This study successfully developed a drug delivery probe dual-labeled with I-124 and Cy5.5 (124I/Cy5.5-Osi/sgRRM2@FCLs), which enabled precise and real-time diagnostic imaging of mouse lung cancer using fluorescence and micro-PET imaging techniques. Additionally, dynamic quantitative monitoring of the drug's targeted delivery and in vivo distribution was performed, confirming that the drug delivery probe specifically targets the tumor region and progressively accumulates in tissues over time, with I-124 signals detectable at the tumor site even up to 72 hours post-administration. Furthermore, the dual-modal drug delivery probe effectively overcame osimertinib resistance in lung cancer by targeting and reversing epithelial-mesenchymal transition (EMT) in tumor cells, inducing ferroptosis, and significantly triggering tumor immunogenic cell death (ICD), thereby enhancing the body's anti-tumor immune response and demonstrating notable anticancer effects."

Lung Cancer • Oncology • Solid Tumor • RRM2

Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-mutant lung cancer. (PubMed, J Thorac Oncol) - "These findings suggest that ARID1A mutations are critical biomarkers for osimertinib resistance and highlight WEE1 inhibition as a promising therapeutic approach for ARID1A-mutant osimertinib-resistant NSCLC."

Journal • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ARID1A • EGFR